Transcode Therapeutics, Inc. (RNAZ) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Transcode Therapeutics, Inc., a Delaware corporation and emerging growth company, on September 11, 2026. The report covers events occurring on September 9, 2026, regarding significant changes in executive leadership and the Board of Directors.
Key Financial Metrics and Compensation
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or debt levels. The primary financial disclosure relates to the separation agreement with the departing Chief Financial Officer:
- Total Potential Severance: Up to $1,250,000.
- Immediate Cash Payment: $416,666.67 payable within 10 days of the effective date.
- Monthly Installments: $416,666.67 payable over 12 months.
- Contingent Payment: Up to $416,666.67, contingent on the company securing $5.0 million or $10.0 million in "Qualified Funding" within one year.
- Equity Grant: Option to purchase 185,000 shares of common stock, vesting monthly over 12 months with acceleration clauses tied to funding milestones.
- Interim CFO Compensation: John Tattory will serve as Interim CFO on a consultant basis through Stout Risius Ross, LLC at an agreed-upon hourly rate.
Material Changes
The filing reports the following material changes effective September 9, 2026:
- Departure of CFO and Director: Thomas A. Fitzgerald resigned as Chief Financial Officer, Principal Financial Officer, Principal Accounting Officer, and member of the Board of Directors. The resignation was not due to any disagreement with the Company.
- Appointment of Interim CFO: John Tattory was appointed as Interim Chief Financial Officer, Principal Financial Officer, and Principal Accounting Officer.
Outlook, Risks, and Management Commentary
The filing highlights a specific financial contingency tied to the company's ability to raise capital. The final portion of the departing CFO's severance and the acceleration of his equity options are directly linked to the company securing $5.0 million or $10.0 million in gross funding within one year of the separation date. This structure suggests that near-term capital raising is a critical operational priority. No other risks, guidance, or unusual items were disclosed in this report.
Key Facts for Investor Verification
- Verify the company's current cash position and runway given the immediate cash severance obligation of approximately $417,000.
- Monitor upcoming capital raising activities to determine if the $5.0 million or $10.0 million funding thresholds will be met, which would trigger additional severance payments and equity acceleration.
- Confirm the hourly rate and expected engagement duration for the Interim CFO, John Tattory, to assess ongoing administrative costs.
- Review the full Separation Agreement (Exhibit 10.1) for any non-compete or non-solicitation clauses that may impact future operations.